Concordant Pre- and Postsynaptic Deficits of Dopaminergic Neurotransmission in Neurologic Wilson Disease

References

1. ↵
   Oder W, Prayer L, Grimm G, et al. Wilson’s disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 1993;43:120–124

   Abstract/FREE Full Text
2. ↵
   Barbosa ER, Caramelli P, Bacheschi LA, et al. Wilson’s disease: magnetic resonance imaging (MRI) with clinical correlations in 16 cases. Rev Paul Med 1993;111(3):407–411

   PubMed
3. ↵
   Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with Parkinsonism. Eur J Nucl Med 1999;26:171–182

   CrossRefPubMedWeb of Science
4. ↵
   Tatsch K, Schwarz J, Oertel WH, Kirsch CM. SPECT imaging of dopamine D2 receptors with ¹²³I-IBZM: initial experience in controls and patients with Parkinson’s syndrome and Wilson’s disease. Nucl Med Commun 1991;12:699–707

   PubMedWeb of Science
5. ↵
   Snow BJ, Bhatt M, Martin WR, Li D, Calne BD. The nigrostriatal dopaminergic pathway in Wilson’s disease studied with positron emission tomography. J Neurol Neurosurg Psych 1991;54:12–17

   Abstract/FREE Full Text
6. ↵
   Westermark K, Tedroff J, Thuomas KA, et al. Neurological Wilson’s disease studies with magnetic resonance imaging and with positron emission tomography using dopaminergic markers. Mov Disord 1995;10:596–603

   CrossRefPubMed
7. ↵
   Schlaug G, Hefter H, Engelbrecht V, et al. Neurological impairment and recovery in Wilson’s disease: evidence from PET and MRI. J Neurol Sci 1996;136:129–139

   CrossRefPubMed
8. ↵
   Oder W, Brücke H, Kollegger H, Spatt J, Asenbaum S, Deecke L. Dopamine D2 receptor binding is reduced in Wilson’s disease: correlation of neurological deficits with striatal ¹²³I-Iodobenzamide binding. J Neural Transm 1996;103:1093–1103

   CrossRef
9. ↵
   Jeon B, Kim J, Jeong JM, et al. Dopamine transporter imaging with [¹²³I]-β-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson’s disease. J Neurol Neurosurg Psych 1998;65:60–64

   Abstract/FREE Full Text
10. ↵
    Biesold D, Günther K. Improved method for investigation of copper metabolism in patients with Wilson’s disease using ⁶⁴Cu. Clin Chem Acta 1972;42:353–359
11. ↵
    Hermann W, Tietze F, Villmann T, Grahmann F, Wagner A. Clinical and fine motor therapy assessment in Wilson’s disease. Nervenarzt 2000;71:970–974

    PubMed
12. ↵
    Barthel H, Sorger D, Kühn HJ, Wagner A, Kluge R, Hermann W. Differential alteration of the nigrostriatal dopaminergic system in Wilson’s disease investigated with [¹²³I] β-CIT and high resolution SPECT. Eur J Nucl Med 2001;28:1656–1663

    PubMed
13. ↵
    van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with Iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175–1181

    Abstract/FREE Full Text
14. ↵
    Toyama H, Ichise M, Ballinger JR, Fornazzari L, Kirsh JC. Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans. Ann Nucl Med 1993;7:29–38

    CrossRefPubMed
15. ↵
    Fletscher N. Movement disorders. In: Donaghy M, ed. Brain’s Diseases of the Nervous System. Oxford: Oxford University Press; 2001:1015–1023
16. ↵
    King AD, Walshe JM, Kendall BE, et al. Cranial MR imaging in Wilson’s disease. AJR Am J Roentgenol 1996;167:1579–1584

    PubMedWeb of Science
17. ↵
    Alanen A, Komu M, Penttinen M, Leino R. Magnetic resonance imaging and proton MR spectroscopy in Wilson’s disease. Br J Radiol 1999;72:749–756

    Abstract
18. ↵
    Magalhaes AC, Caramelli P, Menezes JR, et al. Wilson’s disease: MRI with clinical correlation. Neuroradiology 1994;36:97–110

    CrossRefPubMed
19. ↵
    Weisner B, Hartard C, Dieu C. CSF copper concentration: a new parameter for diagnosis and monitoring therapy of Wilson’s disease with cerebral manifestation. J Neurol Sci 1987;79:2290–2237
20. ↵
    Kodama H, Okabe I, Yanagisawa M, et al. Does CSF copper level in Wilson disease reflect copper accumulation in the brain? Pediatr Neurol 1988;4:35–37

    CrossRefPubMedWeb of Science
21. ↵
    Barbeau A, Friesen H. Treatment of Wilson’s disease with L-dopa after failure with penicillamine. Lancet 1970;1:1180–1181
22. ↵
    Berio A, Vento R, Di Stefano A. Favorable results with an association of L-dopa and amantadine added to penicillamine in the treatment of Wilson’s disease. Minerva Pediatr 1973;25:807–813

    PubMed
23. ↵
    Gelmers HJ, Troost J, Willemse J. Wilson’s disease: Modification by L-dopa. Neuropediatriatrics 1973;4:453–457
24. ↵
    Frankel JP, Hughes A, Lees AJ, Stern GM, Walshe JM. Use of apomorphine to test for dopamine responsiveness in Wilson’s disease. Lancet 1989;2:801–802
25. ↵
    Morgan JP, Preziosi TJ, Bianchine JR. Ineffectiveness of L-dopa as supplement to penicillamine in a case of Wilson’s disease. Lancet 1970;26:659
26. ↵
    Wenning GK, Quinn NP. Parkinsonism: multiple system atrophy. Baillieres Clin Neurol 1997;6:187–204

    PubMed